Regulus Therapeutics reported $41.44M in Cash and Equivalent for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Alnylam Pharmaceuticals ALNY:US $ 745.77M 366.22M
Arena Pharmaceuticals ARNA:US $ 514.18M 81.2M
AstraZeneca AZN:LN 15567M 7931M
Astrazeneca AZN:US $ 15567M 7931M
Biogen BIIB:US $ 1742M 524.5M
Celldex Therapeutics CLDX:US $ 43.45M 25.87M
Dicerna Pharmaceuticals DRNA:US $ 221.21M 62.1M
Gilead Sciences GILD:US $ 7361M 3296M
GlaxoSmithKline GSK:LN 3503M 1254M
Intercept Pharmaceuticals ICPT:US $ 145.62M 52.67M
Intrexon XON:US $ 36.41M 9.06M
Lexicon Pharmaceuticals LXRX:US $ 118.5M 20.85M
Ligand Pharmaceuticals LGND:US $ 301.83M 269.98M
Omeros OMER:US $ 12.7M 3.67M
Regulus Therapeutics RGLS:US $ 41.44M 9.84M
Sangamo Biosciences SGMO:US $ 169.88M 46.9M
Spectrum Pharmaceuticals SPPI:US $ 114.57M 45.05M
Takeda 4502:JP Y 654920M 311302M
Vital Therapies VTL:US $ 87.18M 27.66M
YTE INCY:US $ 1797.58M 127.61M